Targeted therapy for cancer is based on personalized medicine approach

SOMERVILLE, MA — March 2, 2019— Andarix Pharmaceuticals, a leader in the
discovery and development of targeted peptide therapy for cancer announced today that
it has been granted the US trademark for Tozaride by the United States Patent and
Trademark Office.

About Tozaride
Tozaride is a novel, best-in-class cancer therapy based on a radio-labeled somatostatin
peptide analogue. Early clinical studies of Tozaride demonstrated that it is well tolerated
and may produce prolonged stable disease and improved overall survival in advanced
lung cancer patients whose disease has continued to progress after failing other
therapies. Tozaride targeted radiotherapy represents a new treatment paradigm which is
expected to yield significant clinical benefit for both lung cancer (SCLC, NSCLC), and
pancreatic cancer patients. Along with its companion diagnostic that helps identify
patients most likely to respond – those with enough expression of the peptide’s target –
Tozaride could provide another treatment option for patients who are not eligible for, or
who have not responded to current therapies.

About Andarix Pharmaceuticals
Andarix Pharmaceuticals is at the forefront of personalized therapies for cancer,
developing both the imaging agents that can identify appropriate patients, as well as the
targeted therapies for these patients. The company’s products have progressed through
early clinical development. The Andarix technology is based on a proprietary
somatostatin peptide conjugate applicable to lung, pancreatic, neuroendocrine, and
other cancers. Extensive research has demonstrated that somatostatin receptors are
highly up-regulated on several solid tumors, particularly lung, neuroendocrine, and
pancreatic tumors. To learn more about Andarix, please visit .

Andarix Pharmaceuticals

Leave a Comment